Quest PharmaTech Signs Agreement to sell Bionex Technology
Under the terms of the Agreement, Quest will receive $50,000 in cash and 1,351,111 common shares of Toba Industries Ltd. In addition, Quest will also receive $200,000 in the form of future royalties upon successful commercialization of Bionex related products by Peking Marvel. The Agreement is contingent upon TSX Venture Exchange approval of the pending transaction between Peking Marvel and Toba Industries Ltd.
The Bionex Technology comprises a family of novel disinfectants used for multiple applications including hard surface and hand gel disinfectants. Patents have been granted for part of the Technology in USA, Europe and China. The sale of Bionex completes the divesture of non-core products and programs initiated by Quest in 2005.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.